• Publications
  • Influence
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
TLDR
This review focuses on the evolution of iron chelators from initial lead compounds through to the development of novel chelating agents, many of which show great potential to be clinically applied in the treatment of iron overload disease and cancer. Expand
Cellular iron uptake, trafficking and metabolism: Key molecules and mechanisms and their roles in disease.
TLDR
Major aspects of the journey of iron from its initial cellular uptake, its modes of trafficking within cells, to an overview of its downstream utilization in the cytoplasm and within mitochondria are discussed. Expand
Unraveling the mysteries of serum albumin—more than just a serum protein
TLDR
The intracellular localization of albumin was assessed in order to understand the mechanisms and pathways responsible for its uptake, distribution and catabolism in multiple tissues, and this is reviewed herein. Expand
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
TLDR
The current state of lipid-based nanoparticle research is discussed, including the development of liposomes for cancer therapy, different strategies for tumor targeting, liposomal formulation of various anticancer drugs that are commercially available, recent progress in liposome technology for the treatment of cancer, and the next generation of nanoparticles. Expand
Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
TLDR
Detailed investigations of the thiosemicarbazone group of ligands have demonstrated that they are highly effective chelators that, besides RR, also target a range of other molecules including NDRG1 and top2α, all of which contribute to their anticancer effects. Expand
Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
TLDR
The divalent Mn(II), Ni, Cu, and Zn(II) complexes of the HDpT analogues are equally active in preventing proliferation as their ligands, suggesting the complexes act as lipophilic vehicles facilitating intracellular delivery of the free ligand upon metal dissociation. Expand
Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.
TLDR
The most effective HDpT ligands as antiproliferative agents possess considerable lipophilicity and were shown to be charge neutral at physiological pH, allowing access to intracellular Fe pools. Expand
Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents.
TLDR
The alterations in Fe metabolism in tumour cells and the systematic development of novel aroylhydrazone and thiosemicarbazone Fe chelators for cancer treatment are examined. Expand
Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond
TLDR
Chelators originally designed to treat disorders of copper overload, such as penicillamine, trientine, and tetrathiomolybdate, have also emerged as potential anticancer drugs, as they are able to target the key angiogenic cofactor, copper. Expand
2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.
TLDR
This investigation generated the related 2-acetylpyridine thiosemicarbazone (HApT) analogues to examine the influence of the methyl group at the imine carbon and identified structural features necessary to form Fe complexes with potent anticancer activity. Expand
...
1
2
3
4
5
...